New in-house drug testing available for depression, OCD and anxiety medications

by | Jul 15, 2021 | Press Release

We are pleased to announce Cansford can now test in-house for a variety of prescription medications, more commonly used to treat clinical depression, anxiety and OCD in individuals.

Increasing the scope of testing within these drug groups is in response to specific requests from our clients – family law professionals and social workers in particular. Mirtazapine, for example, is an antidepressant medicine – often used to treat depression, sometimes obsessive-compulsive disorder and anxiety disorders.

Our new analyte list includes:

  • Amitryptiline
  • Citalopram
  • Clenbuterol
  • Cyclizine
  • Dimethyltryptamine (DMT)
  • Kratom
  • Methylphenidate
  • Mirtazapine
  • Propranolol
  • Psilocin
  • Sertraline
  • Quetiapine

Samples in our new analyte list will be processed here in the UK, rather than overseas, with a faster turnaround time for our clients and individuals – usually three working days from receipt at our lab.

“Our new testing regimen for specific selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and noradrenergic and specific serotonergic antidepressants (NASSAs), more commonly known as mental health and anti-depressant medications, is in response to a number of requests, many from new and existing clients in family law and social services” says Kim Bagley, Cansford Labs Managing Director.

“Requests are also indicative of government statistics which we are now seeing about people and their mental health in relation to lockdowns and the subsequent Covid-19 pandemic.”

This new list complements our existing 9-drug panel where we can test for nine of the most common drugs such as cannabis, cocaine, opiates and others and additionally, steroids.

Ends

Notes for editors:

For more information email Alex Swann – Alex.Swann@cansfordlabs.co.uk